TherapeuticsMD, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TherapeuticsMD, Inc. on August 21, 2018. The report serves to disclose an investor presentation furnished as Exhibit 99.1, which was intended for use in meetings with investors and analysts on or after the filing date.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a presentation rather than a financial statement containing quantitative performance data.
Material Changes
No material changes to financial performance or operations are detailed within the text of this filing. The report focuses solely on the dissemination of the attached investor presentation.
Guidance, Outlook, and Risks
Management commentary, guidance, and specific risk factors are contained within the attached Exhibit 99.1 (Investor Presentation) rather than the body of this 8-K. The filing explicitly states that the information is furnished pursuant to Regulation FD and is not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the contents of Exhibit 99.1 for actual financial data, strategic outlook, and risk disclosures.
- Note that the information in this 8-K is not subject to the liabilities of Section 18 of the Exchange Act.
- Confirm the date of the investor presentation is August 2018.
- Identify Daniel A. Cartwright as the Chief Financial Officer who authorized the report.